Abstract
Multiple Gαi protein-coupled somatostatin receptors (SSTRs) are expressed in human kidney and liver tissues. Also, aberrant cAMP signaling has been shown to play a critical role in cysto-genesis and enlargement of the human kidney and liver. Thus, somatostatin (SST) analogs become potential and promising alternatives in treating human polystic kidney disease (PKD) and polycystic liver disease (PLD) via interacting with Gαi protein-coupled SSTRs and further blocking cAMP production. Lanreotide is a synthetic, long-acting SST analog with high binding affinity to SSTR2, and has been clinically approved for the treatment of acromegaly due to excessive growth hormone. Recently, this SST analog has been applied in the treatment of PKD and PLD, and has shown an effective reduction of liver and kidney volume compared to placebo. This review will discuss the discovery of this peptide and its clinical applications in the treatment of PKD/PLD patients.
Keywords: cAMP signaling, Lanreotide, Polycystic kidney disease, Polycystic liver disease, Somatostatin, Somatostatin receptors.
Current Topics in Medicinal Chemistry
Title:Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases
Volume: 16 Issue: 2
Author(s): Lichun Sun, Cui-Yun Yu, L. Vienna Mackey and David H. Coy
Affiliation:
Keywords: cAMP signaling, Lanreotide, Polycystic kidney disease, Polycystic liver disease, Somatostatin, Somatostatin receptors.
Abstract: Multiple Gαi protein-coupled somatostatin receptors (SSTRs) are expressed in human kidney and liver tissues. Also, aberrant cAMP signaling has been shown to play a critical role in cysto-genesis and enlargement of the human kidney and liver. Thus, somatostatin (SST) analogs become potential and promising alternatives in treating human polystic kidney disease (PKD) and polycystic liver disease (PLD) via interacting with Gαi protein-coupled SSTRs and further blocking cAMP production. Lanreotide is a synthetic, long-acting SST analog with high binding affinity to SSTR2, and has been clinically approved for the treatment of acromegaly due to excessive growth hormone. Recently, this SST analog has been applied in the treatment of PKD and PLD, and has shown an effective reduction of liver and kidney volume compared to placebo. This review will discuss the discovery of this peptide and its clinical applications in the treatment of PKD/PLD patients.
Export Options
About this article
Cite this article as:
Sun Lichun, Yu Cui-Yun, Mackey L. Vienna and H. Coy David, Lanreotide and its Potential Applications in Polycystic Kidney and Liver Diseases, Current Topics in Medicinal Chemistry 2016; 16 (2) . https://dx.doi.org/10.2174/1568026615666150701115157
DOI https://dx.doi.org/10.2174/1568026615666150701115157 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Promotion of Insulin-Like Growth Factor-I Production by Sensory Neuron Stimulation; Molecular Mechanism(s) and Therapeutic Implications
Current Medicinal Chemistry PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets False Positive of <sup>68</sup>Ga-DOTATATE PET-CT in a Paraganglioma
Endocrine, Metabolic & Immune Disorders - Drug Targets γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets Histone Deacetylases as Targets for Dietary Cancer Preventive Agents: Lessons Learned with Butyrate, Diallyl Disulfide, and Sulforaphane
Current Drug Targets Current Status of Gene Therapy for Hepatocellular Carcinoma, with a Focus on Gene Delivery Approaches
Current Gene Therapy Targeted Delivery of Therapeutics to Urological Cancer Stem Cells
Current Pharmaceutical Design Sleep Duration as a Risk Factor for Cardiovascular Disease- a Review of the Recent Literature
Current Cardiology Reviews Polymeric Carriers for Gene Delivery: Chitosan and Poly(amidoamine) Dendrimers
Current Pharmaceutical Design Development of Peptides as Potential Drugs for Cancer Therapy
Current Pharmaceutical Design Tumor Targeting Using Radiolabeled Antibodies for Image-Guided Drug Delivery
Current Drug Targets A Potencial Theranostic Agent for EGF-R Expression Tumors: 177Lu- DOTA-Nimotuzumab
Current Radiopharmaceuticals Importance of Influx and Efflux Systems and Xenobiotic Metabolizing Enzymes in Intratumoral Disposition of Anticancer Agents
Current Cancer Drug Targets Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Surgical Complications of Hyperglycaemia
Current Diabetes Reviews Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Current Pharmaceutical Design Patented Novelties in Immunoisolation for the Treatment of Endocrine Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Role of NUCB2/nesfatin-1 as a Possible Biomarker
Current Pharmaceutical Design Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry